TP53 and prostate adenocarcinoma: Wertz et al. described, that a cocktail of DO1 and DO7 antibodies could identify 93% of cell lines and patient samples with TP53 missense mutations in the exons 5 to 8 region in prostatic adenocarcinoma [39].